ArticlePloS one2011
Agonist-directed desensitization of the β2-adrenergic receptor.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 48 citations in OpenAlex.
- Biomarker-guided clinical development of the first-in-class anti-inflammatory FPR2/ALX agonist ACT-389949.British journal of clinical pharmacology · 2017Trial
- Pediatric pharmacokinetics and pharmacodynamics of guanabenz for the treatment of vanishing white matter.Scientific reports · 2026Article
- Deciphering complexity of GPCR signaling and modulation: implications and perspectives for drug discovery.Clinical science (London, England : 1979) · 2025Review
- Review
- Boosting Mitochondrial Biogenesis Diminishes Foam Cell Formation in the Post-Stroke Brain.International journal of molecular sciences · 2023Article
- βCell death & disease · 2023Article
- Allosteric modulator potentiates β2AR agonist-promoted bronchoprotection in asthma models.The Journal of clinical investigation · 2023Article
- Decoupling Oxygen Tension From Retinal Vascularization as a New Perspective for Management of Retinopathy of Prematurity. New Opportunities From β-adrenoceptors.Frontiers in pharmacology · 2022Review
- AKAP12 Signaling Complex: Impacts of Compartmentalizing cAMP-Dependent Signaling Pathways in the Heart and Various Signaling Systems.Journal of the American Heart Association · 2020Review
- [Beta 2-adrenergic receptor gene association with overweight and asthma in children and adolescents and its relationship with physical fitness].Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo · 2015Article
- Acoustofluidic chemical waveform generator and switch.Analytical chemistry · 2014Article
- Dynamic mass redistribution analysis of endogenous β-adrenergic receptor signaling in neonatal rat cardiac fibroblasts.Pharmacology research & perspectives · 2014Article
- Divergent label-free cell phenotypic pharmacology of ligands at the overexpressed β₂-adrenergic receptors.Scientific reports · 2014Article
- Label-free drug discovery.Frontiers in pharmacology · 2014Review
- Label-free integrative pharmacology on-target of opioid ligands at the opioid receptor family.BMC pharmacology & toxicology · 2013Article
- Approaches for probing allosteric interactions at 7 transmembrane spanning receptors.Progress in molecular biology and translational science · 2013Review
- Computational study on the different ligands induced conformation change of β2 adrenergic receptor-Gs protein complex.PloS one · 2013Article
- Discovery of 2-(4-methylfuran-2(5H)-ylidene)malononitrile and thieno[3,2-b]thiophene-2-carboxylic acid derivatives as G protein-coupled receptor 35 (GPR35) agonists.Journal of medicinal chemistry · 2011Article
- Label-free integrative pharmacology on-target of drugs at the β(2)-adrenergic receptor.Scientific reports · 2011Article
- Ligand-directed functional selectivity at the mu opioid receptor revealed by label-free integrative pharmacology on-target.PloS one · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
The β(2)-adrenergic receptor (β(2)AR) agonists with reduced tachyphylaxis may offer new therapeutic agents with improved tolerance profile. However, receptor desensitization assays are often inferred at the single signaling molecule level, thus ligand-directed desensitization is poorly understood. Here we report a label-free biosensor whole cell assay with microfluidics to determine ligand-directed desensitization of the β(2)AR. Together with mechanistic deconvolution using small molecule inhibitors, the receptor desensitization and resensitization patterns under the short-term agonist exposure manifested the long-acting agonism of salmeterol, and differentiated the mechanisms of agonist-directed desensitization between a full agonist epinephrine and a partial agonist pindolol. This study reveals the cellular mechanisms of agonist-selective β(2)AR desensitization at the whole cell level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.